Denosumab is an antireceptor activator of nuclear factor- (NF-) kappa ligand (RANK) ligand human monoclonal antibody, which is also a treatment option for bone reduction in metastatic cancers. The gene discussed is TNFRSF11A; the disease is metastatic malignant neoplasm.